insitro

insitro is a private, pre-revenue biotech company pioneering an AI/ML-driven platform for drug discovery. The company combines automated laboratory-generated cellular data with human cohort data to build phenotypic disease models, aiming to identify causal biology and derisk therapeutic development. It is building a wholly-owned and partnered pipeline in metabolism, oncology, and neuroscience, positioning itself at the intersection of cutting-edge biology, data science, and therapeutics. Led by renowned AI researcher Daphne Koller, insitro has secured significant venture funding and major pharmaceutical partnerships to validate its approach.

An integrated, ML-driven platform that generates multi-modal phenotypic data from automated cellular models and combines it with human clinical cohort data. It uses machine learning and generative AI to build phenotypic disease models, leverages human genetics for causal target identification, and aims to derisk multiple steps in the drug R&D value chain.

insitro competes in the rapidly growing AI-driven drug discovery sector against companies like Recursion, Exscientia, Relay Therapeutics, and Absci, as well as internal efforts at large pharma. Its differentiation lies in its fully integrated approach, combining proprietary automated wet-lab data generation with its ML platform, rather than being a pure software player.